Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl- 10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptotheclne] by human hepatic microsomes

Drug Metabolism and Disposition

Volumn 26, Issue 8, 1998, Pages 769-775

  Haaz, Marie Christine ^b   Riché, Christian ^b   Rivory, Laurent P ^b   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECINE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALPHA NAPHTHOFLAVONE; CAMPTOTHECIN; CHLORZOXAZONE; CIMETIDINE; COMPLEMENTARY DNA; COUMARIN; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; IRINOTECAN; KETOCONAZOLE; PIPERIDINE DERIVATIVE; QUINIDINE; RPR 132595A; SULFAPHENAZOLE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENZYME KINETICS; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTRANSFORMATION; CAMPTOTHECIN; CIMETIDINE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KETOCONAZOLE; KINETICS; MICROSOMES, LIVER; TROLEANDOMYCIN;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0031845966     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Berthou F, Ratanasavanh D, Riché C. Picart D, Voisin T and Guillouzo A (1989) Comparison of caffeine metabolism by slices, microsomes and hepatocyte cultures from adult human liver. Xenobiotica 19:401-407.
2. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH (1995) Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225-1230.
3. Dodds HM, Haaz MC, Riou JF, Robert J and Rivory LP (1998) Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578-583.
4. Haaz MC, Rivory LP, Jantet S, Ratanasavanh D and Robert J (1997a) Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 80: 91-96.
5. Haaz MC, Rivory LP, Riché C and Robert J (1997b) The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes: differential hydrolysis for the lactone and carboxylate forms. Naunyn-Schmiedeberg's Arch Pharmacol 356:257-262.
6. Haaz MC, Rivory LP, Riché C, Vernillet L and Robert J (1998) Metabolism of CPT-11 by human hepatic microsomes: participation of cytochrome P450 3A and drug interactions. Cancer Res 58:468-472.
7. Halpert JR, Guengerich FP, Bend JR and Correia MA (1994) Selective inhibitors of cytochromes P450. Toxicol Appl Pharmacol 125:163-175.
8. Jacolot F, Simon I, Dreano Y, Beaune P, Riché C and Berthou F (1991) Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
9. Ladona M, Spalding DJM, Ekman L, Lindström B and Rane A (1989) Human fetal and adult liver metabolism of ethylmorphine: relation to immunodetected cytochrome P450 PCN and interactions with important fetal corticosteroids. Biochem Pharmacol 38:3147-3155.
10. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 227:680-685.
11. Lauritsen K, Laursen LS and Rask-Madsen J (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases. Clin Pharmacokinet 19:94-125.
12. Lokiec F, Monégier du Sorbier B and Sanderink GJ (1996) Irinotecan (CPT-11) metabolites in human bile and urine. Clin Cancer Res 2:1943-1949.
13. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP and Robert J (1997) Pharmacokinetic interrelationhips of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials Clin Cancer Res 3:1261-1266.
14. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commerçon A, Pond SM and Robert J (1996) Identification of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694.
15. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr 661B:133-141.
16. Rivory LP and Robert J (1995) Identification and kinetics of a β-glucuronide of SN-38 in human plasma after administration of the camptothecin derivative irinotecan (CPT-11). Cancer Chemother Pharmacol 36:176-179.
17. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, Sugino E, Yamaguchi K and Miyasaka T (1991) Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxy-camptothecin. Chem Pharm Bull (Tokyo) 39:1446-1454.
18. Slatter JG, Su P, Sams JP, Schaaf LJ and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164.
19. Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA and Guzelian PS (1985) Identification of an inducible form of cytochrome P450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.
20. Waxman D, Attisano C, Guengerich FP and Laperson DP (1988) Human liver microsomal steroid metabolism: identification of the major steroid hormone 6β-hydroxylase cytochrome P450 enzyme Arch Biochem Biophys 263:424-436.
21. Wiseman LR and Markham A (1996) Irinotecan: a review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52:606-623.
22. Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P and Rahmani R (1993) Human liver microsomal cytochrome P4503A isozymes mediated vindesine biotransformation. Biochem Pharmacol 45:853-861.